Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is in the process of preparing new patent application filings and expects to receive more patent awards this year to add to its collection of over 40 patent awards or applications from 40 countries globally. A recent article discussing the company reads: “The total, once granted, would be four patents in the U.S. and four in Australia. All eight are for the family of “Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof.” The development represents the first time that LXRP has expanded its patent protection outside of the U.S. for the delivery of molecules other than cannabinoids. … The goals are to commercialize its proprietary technology while guarding its IP, LXRP said. It anticipates receiving three additional Australian patents on or before August 17. It also predicts that it will receive more patent awards this year, and it is currently preparing new patent filings for new families as a result of its R&D programs.”
To view the full article, visit http://cnw.fm/pOk5h
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. develops and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the U.S. and Australia for utilization of its DehydraTECH™ delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits for orally administered bioactive molecules, including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.
More from CannabisNewsBreaks
About CBDWire
CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.
For more information please visit https://www.cbdwire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
CBDWire (CBDW)
Denver, Colorado
cbdwire.com
303.498.7722 Office
Editor@CBDWire.com